AlphAIalphai — Financial news for AI agents
tradingview.comSEP 31 min read$LTGO

Latigo Biotherapeutics, Inc. 2Q 2026: Net loss $(25.8M), EPS $(27.59) — 10-Q Summary

Latigo Biotherapeutics reported a net loss of $25.8M for 2Q 2026, matching the prior-year quarter, with a diluted net loss per share of $27.59. The company remains pre-revenue. Clinical trials for onzotrigine met key endpoints, and new trials are planned. The company expects cash runway into 2029.

Original reporting
tradingview.com
Published Sep 3, 2026, 8:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 5:57 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Latigo Biotherapeutics, Inc. 2Q 2026: Net loss $(25.8M), EPS $(27.59) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$LTGOBullishMed
01

Why it matters

The earnings release combined with positive trial data provides fresh material that could move the stock.

02

Market read

Earnings and trial data are primary disclosures for a micro‑cap biotech, offering actionable insight.

03

What to watch

Cash runway into 2029 may mitigate short‑term financing concerns.

Relevance 8/10Novelty 8/10Timing: post‑10‑Q release

Background

Latigo Biotherapeutics (LTGO) released its Q2 2026 10‑Q, highlighting financial results and clinical milestones.

Company-level read

Ticker impact

$LTGOBullishHigh confidence
Context

Latigo Biotherapeutics filed its 10‑Q reporting a flat Q2 net loss of $25.8M, EPS loss of $27.59 and disclosed that its pivotal abdominoplasty trial for onzotrigine met primary and key secondary endpoints.

Expected impact

Potential modest upside as investors re‑price clinical progress.

Evidence & confidence

First‑time disclosure of successful pivotal trial results combined with earnings release provides fresh material for price movement.

Market effects

Sector

May boost sentiment in the biotech/clinical‑trial sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact beyond niche biotech community.

Counterpoint

What could challenge this read

Despite trial success, continued pre‑revenue status and cash burn could keep the stock under pressure.

Key entities

  • company
    Latigo Biotherapeutics, Inc.

    Biotech firm developing onzotrigine.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 3
$LTGOHighAI 8/10

Latigo Biotherapeutics posts $25.8M Q2 net loss, $55.0M cash and $397.4M IPO proceeds

Latigo Biotherapeutics reported a Q2 2026 net loss of $25.8M, with $55.0M in cash. The company raised $397.4M in an upsized IPO, expecting funds to last into 2029. R&D and G&A expenses were $21.2M and $4.6M, respectively. The company announced positive trial results for Onzotrigine and plans for further trials. It also initiated a Phase 2 trial for LTG-321 and completed toxicology studies for LTG-418. Naomi Lowy, M.D., was appointed as senior vice president of global regulatory affairs.

tradingview.com2 min
SEP 3
$LTGOHighAI 9/10

Latigo Biotherapeutics, Inc. (LTGO): Results of Operations and Financial Condition

Latigo Biotherapeutics, Inc. (LTGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million;

SEC EDGAR 8-K2 min